Cebranopadol, a Novel Potent Analgesic: Pooled Analysis of Clinical Opiate Withdrawal Scales (PAINWeek 2022) - Sep 19, 2022 - Abstract #21; "Cebranopadol has demonstrated limited physical dependence across a wide range of doses including the high dose of 800μg which is greater than double the highest therapeutic dose that is expected to be used for pain in phase 3 trials. Considering its safety across a wide range of doses, cebranopadol may serve as a much-needed treatment option for patients with moderate to severe pain. Learning Objectives: Upon completion, participant will be able to describe how the development of dependence was monitored during clinical studies with cebranopadol Upon completion, participant will be able to describe the physical dependence observed in patients on cebranopadol vs patients taking comparators including placebo, tapentadol prolonged release, pregabalin, and oxycodone controlled release Upon completion, participant will be able to describe the clinical studies used to study the safety and efficacy of cebranopadol across a variety of pain types"
Retrospective data • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|
|
David Fam, PharmD; Antonio Pardo, MD; James Hackworth, PhD
|